colorectal cancer
-
Adverse Survival Signal Leads G1 to Stop Pivotal Test in Colorectal Cancer
G1 Therapeutics said its drug met the main goal of a Phase 3 study in colorectal cancer, but the preliminary results also show measures of survival are better in the placebo arm. The company is stopping the colorectal cancer study.
-
Takeda Pharma Pays $400M for Global Rights to Colorectal Cancer Drug
The Hutchmed drug, fruquintinib, is already approved in China for colorectal cancer. Takeda Pharmaceutical gets global rights to the small molecule, which has started a rolling submission with the FDA and is being readied for regulatory submissions in Europe and Japan.
-
Payer’s Place: Dawn Maroney
Dawn Maroney, President, Markets of Alignment Health and CEO of Alignment Health Plan, to discuss how they are using technology to provide better service and care to consumers.
-
Owkin’s AI solutions for breast and colorectal cancer receive European approval
The breast cancer solution will help determine which patients would benefit from targeted therapies and which patients could avoid chemotherapy. Meanwhile, the colorectal solution will be able to match patients with the most effective treatment sooner.
-
MedCity Influencers, Devices & Diagnostics, BioPharma
It’s time to integrate liquid biopsy into colorectal cancer treatment decision-making
Since it measures the total amount of circulating DNA (ctDNA) in a patient’s bloodstream using a simple blood draw, ctDNA liquid biopsy tests offers oncologists with an accurate, molecular, real-time cancer detection tool. It also helps to determine cancer staging and can help assess how aggressive the treatment regimen should be.
-
Two fatalities lead Celyad to pause test of off-the-shelf CAR T in colorectal cancer
Celyad Ocology has voluntarily paused a clinical study evaluating its off-the-shelf CAR T-cell therapy in colorectal cancer following the report of two patient deaths. The investigation is ongoing, but the company said that both patients exhibited “similar pulmonary findings.”
-
How we are attempting to turn the tide on colorectal cancer
Stand Up To Cancer and Exact Sciences are teaming up to increase colorectal cancer screening awareness and research such that people don’t have to die from this preventable disease.
-
Combinations seen as preferable for Amgen drug whose ASCO data got ‘meh’ reception
An investigator in the Phase I/II trial of Amgen’s AMG 510 said that while data for colorectal cancer indicated low activity as a single agent, it nevertheless represented a doubling in progression-free survival over what is seen from currently available treatments.
-
Trovagene tries roundabout approach to colorectal cancer with ‘undruggable’ mutation
Although they’re still early, the company presented Phase Ib/II study data showing its PLK1 inhibitor, onvasertib, was able to produce responses in KRAS-mutated metastatic CRC, through a property known as synthetic lethality. KRAS-specific drugs have shown low efficacy in mCRC.
-
Diagnostics, Health Services, Health Tech
Exact Sciences buys fellow oncology diagnostics company Genomic Health for $2.8B
The companies tout the deal as expanding Exact’s commercial footprint to 90 countries and creating a leader in the cancer diagnostic space with projected 2020 revenues of $1.6 billion.
-
Applying Remote Patient Monitoring to Surgery Prep and Recovery, Oncology and Women’s Health
Join us to learn about the latest trends in remote monitoring and how to extend its benefits beyond chronic conditions to more patients – all while using fewer staff resources.
-
Freenome nabs $160M to advance blood-based colorectal cancer test
The South San Francisco company intends to use the funding to launch its pivotal trial for its blood-based colorectal cancer screening and submit its test for parallel review for CMS coverage.
-
Boehringer Ingelheim to acquire Swiss cancer vaccine developer for up to 325M euros
The deal includes an upfront payment and up to 100 million euros in milestones, equaling $364.5 million. Amal’s lead candidate is a vaccine for colorectal cancer expected to enter the clinic later this month.
-
Celyad’s off-the-shelf CAR-T data in colorectal cancer early, but serious toxicities haven’t appeared
Several patients in the trial of CYAD-101 combined with chemotherapy responded to treatment, but both a company executive and a gastrointestinal cancer expert cautioned the data were too preliminary to draw conclusions.
-
Pfizer to buy Array BioPharma for $11.4B
Array markets a two-drug combination for melanoma and recently announced positive data for the the drugs, Braftovi and Mektovi, in colorectal cancer.
-
Hospitals, Artificial Intelligence
This Israeli startup aims to catch disease early with data not diagnostic tests
Medial EarlySign is hoping to leverage the power of artificial intelligence to identify patients at high risk for certain diseases to bend overall cost curve and benefit patients.
-
Startups, BioPharma, Patient Engagement
23andMe gets FDA nod for new Colorectal cancer indication test
The company used its previous authorization for breast cancer genetic screening as a predicate for its 510(k) approval.
Promoted
Payer’s Place: Dr. Anil Singh
Dr. Anil Singh shares his insights into the strategies employed by the organization to identify the most effective digital solutions for their members.
Promoted
Discover the Next-Gen Platform for Integrated Collaborative Care
Beyond EHRs and digital front doors, reducing the gaps in patient care journeys.
